Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Aliya Okey

Nurse Practitioner, Family Glen Dale, WV Nurse Practitioner

NPI 1144001256 CMS profile 11545879

426 8Th St Ste 102, Glen Dale, WV 26038

Open in the dashboard

General payments

$2,122

126 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aliya Okey of Glen Dale, WV is reported in the CMS Open Payments database as having received $2,122 across 126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,220 72
2024 General $789 47
2023 General $113 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aliya Okey
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Aliya Okey were reported at $1,220. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Aliya Okey Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $0 $141 $44–$430 $149
2023 $113 $154 $49–$476 $160
2024 $789 $165 $51–$504 $164
2025 $1,220 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $503 26 payments
  2. Novo Nordisk Inc $337 21 payments
  3. AbbVie, Inc. $288 20 payments
  4. Lilly USA, LLC $218 13 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $132 8 payments
  6. Exact Sciences Corporation $98 6 payments
  7. Xeris Pharmaceuticals, Inc. $88 5 payments
  8. Amgen Inc. $81 5 payments
  9. Novartis Pharmaceuticals Corporation $47 2 payments
  10. ITI, Inc. $45 3 payments
  11. Other $286 17 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,122 126 payments
Products named General payments · program years 2023–2025
  1. BRILINTA $351 16 payments
  2. FARXIGA $232 10 payments
  3. MOUNJARO $173 11 payments
  4. QULIPTA $134 9 payments
  5. UBRELVY $134 9 payments
  6. Kerendia $132 8 payments
  7. ZEPBOUND $112 7 payments
  8. Ozempic $99 6 payments
  9. Wegovy $95 7 payments
  10. GVOKE HYPOPEN $88 5 payments
  11. Other $856 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

1,058

Median for Nurse Practitioner: 389

Drug cost

$86,748

Median for Nurse Practitioner: $21,885

Branded share of claims

18%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 26 $24,463
Eliquis Apixaban Brand 22 $21,531
Mounjaro Tirzepatide Brand 20 $20,355
Trulicity Dulaglutide Brand 12 $11,353
Levalbuterol Tartrate Hfa Levalbuterol Tartrate Brand 12 $646
Potassium Chloride Generic 38 $628
Pantoprazole Sodium Generic 38 $499
Levothyroxine Sodium Generic 46 $492
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $491
Atorvastatin Calcium Generic 50 $373

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRILINTA
  • AstraZeneca Pharmaceuticals LP $81
$81 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $75
$75 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $66
$66 — —
Wegovy
  • Novo Nordisk Inc $65
$65 — —
VRAYLAR
  • AbbVie, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record